Sentence examples for modified hMSC lines from inspiring English sources

The three genetically modified hMSC lines that were established for use in this study are designated as: hMSC-EGFP, hMSC-NT3 and hMSC-NT3-EGFP.

Three genetically modified hMSC lines (EGFP, NT3, NT3-EGFP) were established and used to study cell survival and transgene expression following transplantation in rat spinal cord.

Using these techniques we demonstrate that genetically modified hMSC lines can survive in healthy rat spinal cord when using adequate immune suppression and can serve as vehicles for in vivo transgene expression.

Before transplantation experiments were carried out, transgene expression of these genetically modified hMSC lines was characterised at several passages during culture by PCR, real-time PCR, ELISA and flow cytometry.

In this study, we demonstrate that genetically modified hMSC lines can survive in healthy rat spinal cord over at least 3 weeks by using adequate immune suppression and can serve as vehicles for transgene expression.

We observed no changes in proliferation of U87wt cells in co-culture with control or scFvEGFRvIII modified hMSC.

The use of genetically modified hMSC with scFv to EGFRvIII and other tumor specific antigens might eliminate the need of repetitive inoculation of hMSC to achieve the prolonged and desired therapeutic effect.

Of note, while there is clear heterogeneity in EGFRvIII expression in brain tumors, the enhanced benefit of targeting modified hMSC should result in a bystander effect to cells which do not express EGFRvIII.

Following genetic modification of hMSC with a DNA plasmid encoding the EGFP reporter gene and successful in vivo transplantation and detection of hMSC-EGFP cells, we genetically modified hMSC with a similar DNA plasmid-encoding rat NT3 (see Figure 1A, pCMV-NT3 plasmid).

Flow cytometric analysis was used for routine (weekly) and pre-transplant measurement of EGFP transgene expression and cell viability of harvested genetically modified hMSC populations.

However, before genetically modified hMSC can potentially be used in a clinical setting to treat spinal cord injuries, more research on standardisation of hMSC culture and genetic modification needs to be done in order to prevent tumour formation and transgene silencing in vivo.